MINERALYS THERAPEUTICS INC (MLYS) Stock Overview
NASDAQ:MLYS - US6031701013 - Common Stock
MLYS Key Statistics, Chart & Performance
The current stock price of MLYS is 15.22 USD. In the past month the price increased by 7.56%. In the past year, price increased by 22.64%.
MLYS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.63 | 367.30B | ||
| AMGN | AMGEN INC | 13.1 | 153.76B | ||
| GILD | GILEAD SCIENCES INC | 14.54 | 139.67B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.14 | 100.52B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.7 | 61.43B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.29B | ||
| ARGX | ARGENX SE - ADR | 75.95 | 43.09B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.02 | 35.42B | ||
| INSM | INSMED INC | N/A | 28.53B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.50B | ||
| NTRA | NATERA INC | N/A | 23.04B | ||
| BIIB | BIOGEN INC | 8.29 | 19.45B |
Related stock screener links
About MLYS
Company Profile
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. The company is headquartered in Radnor, Pennsylvania and currently employs 51 full-time employees. The company went IPO on 2023-02-10. The firm is focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The company has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). The company is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and in subjects with hypertension and OSA.
Company Info
MINERALYS THERAPEUTICS INC
150 N. Radnor Chester Road, Suite F200
Radnor PENNSYLVANIA US
Employees: 51
Phone: 18883786240
MINERALYS THERAPEUTICS INC / MLYS FAQ
What is the stock price of MINERALYS THERAPEUTICS INC today?
The current stock price of MLYS is 15.22 USD. The price increased by 0.07% in the last trading session.
What is the ticker symbol for MINERALYS THERAPEUTICS INC stock?
The exchange symbol of MINERALYS THERAPEUTICS INC is MLYS and it is listed on the Nasdaq exchange.
On which exchange is MLYS stock listed?
MLYS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MINERALYS THERAPEUTICS INC stock?
15 analysts have analysed MLYS and the average price target is 36.98 USD. This implies a price increase of 142.94% is expected in the next year compared to the current price of 15.22. Check the MINERALYS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MINERALYS THERAPEUTICS INC worth?
MINERALYS THERAPEUTICS INC (MLYS) has a market capitalization of 1.01B USD. This makes MLYS a Small Cap stock.
How many employees does MINERALYS THERAPEUTICS INC have?
MINERALYS THERAPEUTICS INC (MLYS) currently has 51 employees.
What are the support and resistance levels for MINERALYS THERAPEUTICS INC (MLYS) stock?
MINERALYS THERAPEUTICS INC (MLYS) has a support level at 14.46 and a resistance level at 15.3. Check the full technical report for a detailed analysis of MLYS support and resistance levels.
Should I buy MINERALYS THERAPEUTICS INC (MLYS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MLYS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MLYS, evaluating the profitability, health, valuation and growth aspects
- MINERALYS THERAPEUTICS INC (MLYS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MINERALYS THERAPEUTICS INC (MLYS) Sales and EPS estimates to see what analysts future expectations are.
- MINERALYS THERAPEUTICS INC (MLYS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MINERALYS THERAPEUTICS INC (MLYS) Insider and Institutional Ownership to learn about the owners and their transactions.
- MINERALYS THERAPEUTICS INC (MLYS) Stock Chart to make your own analysis
- MINERALYS THERAPEUTICS INC (MLYS) Latest news and press-releases to stay up to date.
Does MINERALYS THERAPEUTICS INC (MLYS) stock pay dividends?
MLYS does not pay a dividend.
When does MINERALYS THERAPEUTICS INC (MLYS) report earnings?
MINERALYS THERAPEUTICS INC (MLYS) will report earnings on 2025-11-10.
What is the Price/Earnings (PE) ratio of MINERALYS THERAPEUTICS INC (MLYS)?
MINERALYS THERAPEUTICS INC (MLYS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.56).
What is the Short Interest ratio of MINERALYS THERAPEUTICS INC (MLYS) stock?
The outstanding short interest for MINERALYS THERAPEUTICS INC (MLYS) is 10.89% of its float. Check the ownership tab for more information on the MLYS short interest.
MLYS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to MLYS. When comparing the yearly performance of all stocks, MLYS turns out to be only a medium performer in the overall market: it outperformed 65.29% of all stocks.
MLYS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MLYS. While MLYS has a great health rating, there are worries on its profitability.
MLYS Financial Highlights
Over the last trailing twelve months MLYS reported a non-GAAP Earnings per Share(EPS) of -3.56. The EPS decreased by -31.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.82% | ||
| ROE | -60.84% | ||
| Debt/Equity | 0 |
MLYS Forecast & Estimates
15 analysts have analysed MLYS and the average price target is 36.98 USD. This implies a price increase of 142.94% is expected in the next year compared to the current price of 15.22.